pmid,title,journal,year,drug,disease
38864452,Risk of Adverse Events in Anticoagulated Patients With Atrial Fibrillation and Nonalcoholic Fatty Liver Disease.,The Journal of clinical endocrinology and metabolism,2024,Warfarin,Non-alcoholic Fatty Liver Disease
38187513,The Association Between Non-Clinically Apparent Liver Fibrosis and Pulmonary Arterial Hypertension in Hispanic Patients.,Cardiology research,2023,Warfarin,Non-alcoholic Fatty Liver Disease
36837547,Oral Anticoagulation in Patients with Chronic Liver Disease.,"Medicina (Kaunas, Lithuania)",2023,Warfarin,Non-alcoholic Fatty Liver Disease
36233052,A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure.,International journal of molecular sciences,2022,Warfarin,Non-alcoholic Fatty Liver Disease
34525124,Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH).,PloS one,2021,Warfarin,Non-alcoholic Fatty Liver Disease
32285340,Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review.,Advances in therapy,2020,Warfarin,Non-alcoholic Fatty Liver Disease
18095746,Orlistat-associated adverse effects and drug interactions: a critical review.,Drug safety,2008,Warfarin,Non-alcoholic Fatty Liver Disease
